Prince Henry’s Institute

 

Peter Fuller

 

Appointments

• Senior Principal Research Fellow, NHMRC

• Adjunct Professor, Monash University

• Head, Endocrinology Unit, Southern Health

 

Profile

Professor Fuller is a physician-scientist active in basic research and clinical endocrinology.  He trained in Melbourne in both clinical endocrinology and molecular endocrinology before postdoctoral training at the Massachusetts General Hospital in Boston.  Professor Fuller was awarded a Wellcome Trust Australian Senior Research Fellowship in 1987 and has received the Eric Susman Prize from the Royal Australasian College of Physicians. His doctoral studies were under the supervision of John Funder at the Prince Henry's Hospital Medical Research Centre. He became a Senior Scientist at the Insititute in 1987.

 

Research Interests

His research interests lie primarily in understanding the molecular mechanisms of steroid hormone action.  His laboratory also studies the molecular pathogenesis of granulosa cell tumours of the ovary.

 

Expertise

clinical endocrinology, molecular endocrinology

 

Recent Achievements

•  Awarded Life Membership of the Endocrine Society of Australia.

 

 Service to Scientific Community

• 2007- Inaugural Member, Victorian Cancer Agency, Consultative Council

• 2003-  Board of the Cancer Council of Victoria

• 2007-2011, Associate Editor, Endocrinology

• 2008- Chair, Career Advancement Award Committee, Murdoch Childrens Research Institute

• 2007- Governor, Florey Neurosciences Institute

• 2000-2007, Board of the Howard Florey Institute

• 2003-2006, Chair the NHMRC Enabling Grants Committee

• 2005- Council of the Cabrini Education and Research Institute

• 2000-2003, Chair of the NHMRC Training Awards Committee

• 2000-2003, Member of the NHMRC Research Committee

• 1994-1996, President of the Endocrine Society of Australia

• Ministerial (Victorian) Task Force on Cancer and of its Research Working Group

• Editorial Boards of Steroids, Endocrinology, Journal of Molecular Endocrinology, Hormone and Metabolic Research, Expert Opinion on Investigative drugs

• Recipient of project grants from NHMRC, Anti-Cancer Council of Victoria and the National Heart Foundation

 

Current Research

• Structure - function relationships of the mineralcorticoid receptor

• Mineralcorticoid receptor regulation of gene expression

• Molecular pathogenesis of granulosa cell tumours of the ovary

• Role of ERβ in folliculogenesis

• Ovarian phenotype of the IKKβ condition

 

Selected Publications

Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of Mineralocorticoid Receptors From Macrophages Protects Against Deoxycorticosterone/Salt-Induced Cardiac Fibrosis and Increased Blood Pressure. Hypertension. 2009 Jul 27.

Pippal JB, Yao Y, Rogerson FM, Fuller PJ. Structural and functional characterisation of the interdomain interaction in the mineralocorticoid receptor. Mol Endocrinol. 2009 Jun 18.

Chu S, Alexiadis M, Fuller PJ. Proteasome Inhibition by Bortezomib Decreases Proliferation and Increases Apoptosis in Ovarian Granulosa Cell Tumors. Reproductive Sciences. 2009 Apr;16(4):397-407.

Bittinger S, Alexiadis M, Fuller PJ. Expression status and mutational analysis of the PTEN and P13K subunit genes in ovarian granulosa cell tumors. Int J Gynecol Cancer. 2009 Apr;19(3):339-42.

Bilandzic M, Chu S, Farnworth PG, Harrison C, Nicholls P, Wang Y, et al. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol Endocrinol. 2009 Apr;23(4):539-48.

Wong J, Lu Z, Doery J, Fuller P. Lessons from a review of thyroglobulin assays in the management of thyroid cancer. Internal Medicine Journal. 2008;38(6 A):441-4.

Stenvers K, Bilandzic M, Chu S, Farnworth P, Escalona R, Wang Y, et al., editors. Loss of betaglycan expression contributes to malignant properties of human granulosa tumor cells. World Congress on Reproductive Biology; 2008 May 24-25; Kailua Kona, HI.

Jamieson S, Fuller PJ. Management of granulosa cell tumour of the ovary. Current Opinion in Oncology. 2008 Sep;20(5):560-4.

Chu S, Alexiadis M, Fuller PJ. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecologic Oncology. 2008;108(1):182-90.

Rogerson FM, Yao YZ, Elsass RE, Dimopoulos N, Smith BJ, Fuller PJ. A critical region in the mineralocorticoid receptor for aldosterone binding and activation by cortisol: evidence for a common mechanism governing ligand binding specificity in steroid hormone receptors. Mol Endocrinol. 2007 Apr;21(4):817-28.

McNeilage J, Alexiadis M, Susil BJ, Mamers P, Jobling T, Laslett G, Trajstman A, and Fuller PJ. 2007. Molecular characterization of sarcomatous change in a granulosa cell tumor. Int J Gynecol Cancer 17:398.

Rogerson FM, Yao YZ, Elsass RE, Dimopoulos N, Smith BJ, and Fuller PJ. 2007. A critical region in the mineralocorticoid receptor for aldosterone binding and activation by cortisol: evidence for a common mechanism governing ligand binding specificity in steroid hormone receptors. Mol Endocrinol 21:817.

Brennan FE and Fuller PJ. 2006. Mammalian K-ras2 is a corticosteroid-induced gene in vivo. Endocrinology 147:2809.